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Activation of the galanin receptor 2 in the
periphery reverses nerve injury-induced allodynia
Richard P Hulse1,2, David Wynick1,2* and Lucy F Donaldson1
Abstract
Background: Galanin is expressed at low levels in the intact sensory neurons of the dorsal root ganglia with a
dramatic increase after peripheral nerve injury. The neuropeptide is also expressed in primary afferent terminals in
the dorsal horn, spinal inter-neurons and in a number of brain regions known to modulate nociception. Intrathecal
administration of galanin modulates sensory responses in a dose-dependent manner with inhibition at high doses.
To date it is unclear which of the galanin receptors mediates the anti-nociceptive effects of the neuropeptide and
whether their actions are peripherally and/or centrally mediated. In the present study we investigated the effects of
direct administration into the receptive field of galanin and the galanin receptor-2/3-agonist Gal2-11 on
nociceptive primary afferent mechanical responses in intact rats and mice and in the partial saphenous nerve injury
(PSNI) model of neuropathic pain.
Results: Exogenous galanin altered the responses of mechano-nociceptive C-fibre afferents in a dose-dependent
manner in both naive and nerve injured animals, with low concentrations facilitating and high concentrations
markedly inhibiting mechano-nociceptor activity. Further, use of the galanin fragment Gal2-11 confirmed that the
effects of galanin were mediated by activation of galanin receptor-2 (GalR2). The inhibitory effects of peripheral
GalR2 activation were further supported by our demonstration that after PSNI, mechano-sensitive nociceptors in
galanin over-expressing transgenic mice had significantly higher thresholds than in wild type animals, associated
with a marked reduction in spontaneous neuronal firing and C-fibre barrage into the spinal cord.
Conclusions: These findings are consistent with the hypothesis that the high level of endogenous galanin in
injured primary afferents activates peripheral GalR2, which leads to an increase in C-fibre mechanical activation
thresholds and a marked reduction in evoked and ongoing nociceptive responses.
Introduction
The neuropeptide galanin is expressed at low levels in
~5% of small diameter neurons in the intact adult
rodent dorsal root ganglion (DRG) [1-3]. Higher levels
of the peptide are also detected in the primary afferent
terminals of the spinal cord (lamina II), the dorsal horn
inter-neurons [4], and in a number of brain regions
known to modulate nociception, including the arcuate
nucleus and periaqueductal grey (PAG) [5,6]. After
nerve injury and models of neuropathic pain, galanin
expression is markedly increased in 30-40% of sensory
neurons [7,8] and in the primary afferent terminals in
the superficial layers of the dorsal horn [9].
Behavioural studies have demonstrated that intrathecal
(i.t.) administration of galanin modulates nociception in
a dose-dependent manner, with facilitation of nocicep-
tive reflexes at low concentrations of galanin [10,11] and
a striking inhibition at higher concentrations [12,13].
The anti-nociceptive effect of high dose galanin is
enhanced following peripheral nerve injury [14,15]. Con-
sistent with the central effects of galanin, subcutaneous
injection of galanin into the receptive fields of wide
dynamic range dorsal horn neurons (lamina V) inhibited
noxious mechanically evoked activity in intact and nerve
injured rats [15]. The anti-nociceptive effects of galanin
are further substantiated by a number of different lines
of galanin over-expressing (Gal-OE) transgenic mice
which all have an increase in withdrawal thresholds in
the intact state and/or a reduction in allodynia after
nerve injury [16,17].
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The observed anti-nociceptive effects of high levels of
endogenous or exogenous galanin are mediated by the
activation of one or more G-protein coupled galanin
receptors (GalR1, GalR2 and GalR3). Studies using in-
situ hybridization have shown that GalR1 and GalR2
mRNAs are expressed by 51% and 83% of adult rat
DRG neurons, respectively [18]. The levels of both sub-
types decrease after axotomy [19-21]. High levels of
GalR1 are observed in the spinal inter-neurons in the
dorsal horn of the spinal cord with no change after
axotomy [22]. In contrast, there is very little GalR2
mRNA in the spinal inter-neurons in the dorsal horn
[22,23]. Expression of GalR3 in the rodent spinal cord
and DRG is very low as determined by RT-PCR [21,24],
and undetectable using in-situ hybridisation [25].
The short half-life of galanin and Gal2-11 (a peptide
fragment of galanin with 500-fold selectivity for GalR2
and GalR3, compared to GalR1 [26,27]) in plasma of
less than 10 minutes [28,29], and the absence of high-
affinity galanin receptor-specific pharmacological tools
have largely precluded a detailed analysis of the roles
played by each receptor subtype in nociception. A pre-
vious study using i.t. infusions of galanin or Gal2-11 in
a rat neuropathic pain model concluded that the central
anti-nociceptive effects of galanin are likely to be
mediated by activation of GalR1 [26], consistent with
the very low levels of GalR2 in the dorsal horn [22].
However, GalR1-KO mice have only minor changes in
neuropathic pain in two different models [30,31].
Further, the recently described developmental deficits in
the DRG of GalR2-KO mice [21] precludes an analysis
of the nociceptive role played by GalR2 in the adult ani-
mal. To date, the nociceptive phenotype of a GalR3-KO
mouse has not yet been published.
In summary, it has not been possible to directly ana-
lyse whether the anti-nociceptive actions of galanin are
principally peripherally and/or centrally mediated, nor
to dissect the roles played by each galanin receptor sub-
type in nociceptive processing in the adult animal. The
aim of the present study was to test the hypothesis that
peripheral activation of GalR2 can modulate nociceptive
C-fibre afferent mechanical responses in naive rats and
mice and that these effects are altered in the PSNI
model of neuropathic pain. Here we show that adminis-
tration of low concentrations of galanin and Gal2-11
directly into the receptive field of intact but injured sen-
sory afferents facilitates, and high concentrations mark-
edly inhibit mechano-nociceptor activity. Further,
mechano-sensitive nociceptors in Gal-OE mice had sig-
nificantly higher thresholds after PSNI than in WT
mice, associated with an abolition of spontaneous neu-
ronal firing, the neural correlate of ongoing pain.
These findings are consistent with the hypothesis that
the high level of endogenous galanin in injured primary
afferents activates peripheral GalR2, which leads to an
increase in C-fibre mechanical activation thresholds and
a marked reduction in evoked and ongoing nociceptive
responses. This would be expected to lead to a decrease
in C-fibre barrage into the spinal cord, which in turn
would reduce central sensitisation and allodynia.
Results
Nociceptive effects of galanin are mediated via activation
of GalR2 in intact rats and mice
We first studied whether administration of galanin into
the peripheral receptive field modulates neuronal activity
of mechanically sensitive cutaneous primary afferents.
We also tested whether these effects were dose-depen-
dent, using doses similar to those previously described to
cause facilitation and suppression by i.t. administration
[32]. In adult intact naïve rats, subcutaneous (s.c.) injec-
tion of 10 nM galanin into the peripheral receptive field
of C-fibre nociceptors had no effect on the threshold of
these fibres (data not shown). However, 100 nM galanin
lowered mechanical activation thresholds (*p < 0.05, sal-
ine 18.0 ± 4.62 g vs galanin 4.5 ± 1.26 g, Figure 1A). In
contrast, 10 uM galanin s.c. led to a striking increase in
mechanical threshold in C-fibre mechano-nociceptors (*p
< 0.01, saline 17.75 ± 2.75 g vs galanin 47.5 ± 12.50 g,
Figure 1B and Figure 2A &2B). Of note, 10 uM galanin
did not alter mechanical thresholds in low threshold
mechanically sensitive A-beta fibres, (CV = 22.5-28 m/s)
in the intact rat (baseline 0.9333 ± 0.53 vs saline 0.9333 ±
0.53 vs 10 uM galanin 1.133 ± 0.47, NS).
We then confirmed that similar responses to galanin
in mechanically sensitive C-fibre afferents were also pre-
sent in mice. In adult intact naive CBA/Bl6 mice 10 uM
galanin was injected subcutaneously into the peripheral
receptive field of C-fibre nociceptors. This increased
mechanical thresholds (*p < 0.05, baseline 0.9 ± 10.32 g
vs galanin 20 ± 0.55 g, Figure 1C and Figure 3A &3B)
and reduced mechanically evoked activity (*p > 0.05, 2 g
saline 8.66 ± 5.06Hz vs galanin 1.09 ± 0.63Hz, Figure
1D). As with the rat, 10 uM galanin s.c. had no effect
on mechanical thresholds of A-beta fibres (CV = 12.5-
18 m/s) in the adult intact naïve mouse (baseline 0.34 ±
0.06 g vs galanin 0.28 ± 0.07 g, NS).
We next used the GalR2/3 agonist, Gal2-11 to test
whether the above responses to galanin were mediated
via activation of GalR2. As discussed above, the expres-
sion of GalR3 mRNA in the DRG and dorsal horn is
undetectable by in-situ hybridization and we therefore
reasoned that the observed responses to Gal2-11 must
be attributable to GalR2 activation. Identical doses of
Gal2-11 to those used with galanin were directly applied
to the peripheral receptive fields of C-fibre nociceptors
in adult intact naïve rats. 100 nM Gal2-11 s.c. reduced
mechanical activation thresholds (*p < 0.05, baseline
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18.25 ± 4.83 g vs Gal2-11 3.10 ± 1.17 g, Figure 4A) and
increased mechanically evoked activity (*p < 0.05, 4 g
saline 0.35 ± 0.21Hz vs Gal2-11 2.12 ± 0.96Hz, Figure
4B). In contrast, 10 uM Gal2-11 s.c. markedly increased
mechanical activation thresholds (*p < 0.05, baseline
25.2 ± 9.73 g vs Gal2-11 102.4 ± 34.44 g, Figure 4C)
and decreased mechanically evoked activity (*p < 0.05, 4
g saline 1.15 ± 0.33Hz vs Gal2-11 0.088 ± 0.06Hz, Fig-
ure 4D). These findings are very similar to those
observed with galanin and imply that the effects of gala-
nin are largely dependent upon activation of GalR2.
Nociceptive responses to galanin in the PSNI model of
neuropathic pain
We then investigated whether the above dose-dependent
effects of peripherally administered galanin and Gal2-11
were maintained in a model of neuropathic pain. We
and others have shown that partial ligation of the saphe-
nous nerve (PSNI) in rats and mice induces a robust
increase in mechanical allodynia three days after saphe-
nous nerve injury which lasts for at least 14 days
[33,34], and induces a marked upregulation in galanin
expression in the L3 and L4 DRG [33]. The simplicity of
the PSNI model due to the superficial position of the
saphenous nerve, minimally invasive surgery and the
ability to easily record from intact (ie non-axotomised)
nociceptive afferents has made it an attractive model to
study injured primary afferents in an almost pure sen-
sory nerve [33,34].
Nerve injured adult rats were used three days after
PSNI when the degree of mechanical allodynia had
reached its peak [33] and all data below are from
Figure 1 Responses of mechano-C fibre nociceptors following peripheral administration of galanin in rat and mouse. Subcutaneous
injections of galanin were administered locally into the receptive field of mechanical nociceptive C-fibre afferents in intact naïve rodents. [A] 100
nM galanin significantly reduced mechanical activation thresholds in rats compared to vehicle (one way ANOVA with post-hoc Bonferroni
multiple comparison test, *p < 0.05, n = 4). [B] 10 uM galanin, significantly increased mechanical thresholds in rats compared to vehicle (one
way ANOVA with post-hoc Bonferroni multiple comparison test, *p < 0.05, n = 4). [C] 10 uM galanin significantly increased mechanical activation
thresholds in mice (one way ANOVA, *p < 0.05, n = 5) and [D] 10 uM galanin significantly attenuated mechanically evoked activity to a 2 g von
Frey hair in mice (one way ANOVA with post-hoc Bonferroni multiple comparison test, * p < 0.05, n = 5).
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primary afferents that have intact receptive fields in the
hindpaw ipsilateral to the injury. 100 nM galanin s.c. (*p
< 0.05, baseline 7.20 ± 1.20 g vs galanin 1.20 ± 0.2 g,
Figure 5A) and 100 nM Gal2-11 s.c. (**p < 0.01, baseline
4.67 ± 0.67 g vs Gal2-11 1.0 ± 0.23 g, Figure 5B) both
led to a significant reduction in mechanical activation
thresholds. In contrast, 10 uM galanin s.c. (**p < 0.01,
baseline 7.75 ± 2.46 g vs galanin 16.50 ± 3.38 g, Figure
5C) and 10 uM Gal2-11 s.c. (*p < 0.05, baseline 3.48 ±
0.82 g vs Gal2-11 8.60 ± 2.09 g, Figure 5D) significantly
increased mechanical thresholds. When normalised to
baseline, data demonstrate that 10 uM galanin and 10
uM Gal2-11 are equipotent in both intact naïve (Figure
6A) and neuropathic rats (Figure 6B).
Endogenous over-expression of galanin attenuates
allodynia through actions on the primary nociceptor
We applied the PSNI model to the previously described
Gal-OE and strain-matched WT mice. The Gal-OE
mice over-express galanin in the DRG, spinal cord and
brain under the control of the 20-kb galanin promoter
[17,35] and have a 4-fold increase in the levels of gala-
nin in the DRG (measured by radioimmunoassay) com-
pared to WT mice, one week after axotomy [36]. Intact
mice of both genotypes had similar mechanical withdra-
wal thresholds (Figure 7A). PSNI resulted in a rapid
onset of mechanical allodynia in WT mice that was
greatly attenuated in the Gal-OE. The WT mice
remained allodynic for the duration of the experiment,
whereas the withdrawal thresholds in the Gal-OE mice
returned to baseline intact values by day 4 after PSNI
and remained so for the remainder of the experiment.
These behavioural findings are very similar to those pre-
viously published using the sciatic nerve spared nerve
injury model of neuropathic pain [17].
To determine whether the reversal of the mechanical
allodynia after PSNI in the Gal-OE mice was attributa-
ble to altered primary afferent properties, cutaneous pri-
mary mechano-sensitive afferents were studied in Gal-
OE mice seven days after PSNI (when the allodynia had
returned to intact baseline values) and compared to allo-
dynic WT mice. Mechano-sensitive nociceptors (pooled
C- and A delta fibres with conduction velocities (CV) of
0.33-8.5 m/s) in Gal-OE mice after PSNI had signifi-
cantly higher thresholds than those from naïve Gal-OE
mice (*p < 0.05, naïve Gal-OE 2.97 ± 0.99 g vs PSNI
Gal-OE 14.75 ± 4.03 g, Figure 7B). In contrast, thresh-
olds fell in WT animals after PSNI (p < 0.05, naïve WT
Figure 2 Representative traces of a rat mechano-C fibre
nociceptor in response to 10 μM galanin. [A] C fibre
mechanically sensitive nociceptor that responds to a 10 g von Frey
hair. [B] Subcutaneous injection of 10 μM galanin into the receptive
field led to an increase in mechanical activation threshold to 60 g.
Figure 3 Representative traces of a mouse mechano-C fibre
nociceptor in response to 10 μM galanin. [A] C fibre
mechanically sensitive nociceptor that responds to a 2 g von Frey
hair. [B] Subcutaneous injection of 10 μM galanin into the receptive
field led to an increase in mechanical activation threshold to 4 g.
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5.33 ± 1.33 g vs PSNI WT 1.35 ± 0.24 g, Figure 7B). No
significant differences in thresholds were noted in intact
naïve Gal-OE vs WT mice (Figure 7B). In addition,
nociceptor spontaneous activity (PSNI WT 0.41 ±
0.25Hz vs PSNI Gal-OE 0.023 ± 0.014, p < 0.05) and
the calculated afferent barrage [37,38] into the spinal
cord (PSNI WT 749.7 ± 450.6Hz vs PSNI Gal-OE 41.76
± 53.62Hz, p < 0.05) were both greatly attenuated in the
injured Gal-OE mice compared to injured WT mice. In
contrast to these findings, no changes in mechanical
activation threshold (naïve WT 0.32 ± 0.08 g vs naïve
Gal-OE 0.38 ± 0.08 g vs PSNI WT 0.24 ± 0.08 g vs
PSNI Gal-OE 0.34 ± 0.08 g, Figure 7C) or spontaneous
activity (naïve WT 0.1 ± 0.1Hz vs naïve Gal-OE 0.08 ±
0.04Hz vs PSNI WT 0.16 ± 0.14Hz vs PSNI Gal-OE
0.04 ± 0.21) were observed in intact injured A beta
fibres (CV = 8-22 m/s).
These findings of an increase in C-fibre mechanical
activation thresholds and spontaneous nociceptive
responses are compatible with the observed reversal in
allodynia in the Gal-OE mice, and support the hypoth-
esis that the high levels of endogenous galanin in
injured primary afferents activate a peripheral GalR2
mediated anti-nociceptive pathway.
Discussion
The roles played by galanin and its receptor subtypes in
nociception and its principal sites of action have yet to
be fully defined. In this paper we have focused on the
primary nociceptor and have investigated the effects of
peripherally administered galanin and Gal2-11 (neither
of which would be expected to cross the blood-brain-
barrier) in rat and mouse, in the intact state and after
the PSNI model of neuropathic pain. Our findings
demonstrate that the principal effects of peripherally
administered galanin are on high threshold C-fibre
mechano-sensitive (HTM) primary afferents i.e. nocicep-
tors. In intact adult animals the mechanically-evoked
thresholds of nociceptive afferents is enhanced by s.c.
administration of low doses of galanin or Gal2-11
Figure 4 Mechanical responses of C fibre nociceptors following GalR2 activation. Subcutaneous injections of Gal2-11 were administered
locally into the receptive field of mechanical nociceptive C-fibre afferents in intact naïve rats. [A] 100 nM Gal2-11 significantly decreased
activation thresholds (one way ANOVA with post-hoc Bonferroni multiple comparison test, * p < 0.05, n = 4), and [B] facilitated mechanically
evoked activity to a 4 g von Frey hair (one way ANOVA with post-hoc Bonferroni multiple comparison test, * p < 0.05, n = 4). [C] 10 uM Gal2-11
significantly increased mechanical activation thresholds (one way ANOVA with post-hoc Bonferroni multiple comparison test, * p < 0.05, n = 5),
and [D] significantly decreased mechanically evoked activity to a 4 g von Frey hair (one way ANOVA with post-hoc Bonferroni multiple
comparison test, *p < 0.05, n = 5).
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directly into the receptive field, whilst at higher concen-
trations the mechanical thresholds of HTM afferents are
greatly inhibited. This suggests that galanin has a similar
dose-dependent effect on primary afferent nociceptors
to those previously reported with respect to the spinal
flexor reflex [12,39]. Of note, the same dose ranges of
galanin s.c. were used in this study as had been pre-
viously used by Wiesenfeld-Hallin and colleagues by i.t.
administration [12], and in both studies 30-300 nM
galanin stimulated and 3-30 uM inhibited both nocicep-
tor and spinal flexor reflex activity.
Having demonstrated a clear biphasic nociceptive
response to peripherally administered galanin and Gal2-
11 in the intact adult rodent we then used the PSNI
neuropathic pain model to study the effects of periph-
eral administration of both ligands and transgenic over-
expression of the neuropeptide on peripheral sensitisa-
tion. There is now widespread acceptance that the beha-
vioural hypersensitivity that follows nerve injury is
attributable to sensitisation of neuronal networks in the
central nervous system [40-42]. In addition, it is likely
that the hyperalgesia and allodynia that occurs in many
neuropathic pain states is dependent, at least in part, on
peripheral sensitisation, with increases in C-fibre barrage
from the injured primary afferents into the spinal cord,
inducing and maintaining central sensitisation
[38,43,44]. We have previously shown that the PSNI
model results in peripheral sensitisation of mechanically
sensitive afferents in the rat and mouse, with a marked
increase in spontaneous mechano-nociceptor activity
[37]. Further, the spontaneous activity after PSNI in the
mouse of 0.5Hz is associated with a 20-fold increase in
the primary afferent barrage into the spinal cord which
has previously been shown to be critical to the induc-
tion of central sensitisation [45].
Our findings in the rat after PSNI demonstrate that s.
c. administration of 100 nM galanin or Gal2-11
decreased, and 10 uM increased, the mechanical
Figure 5 C fibre nociceptor mechanical responses after galanin and Gal2-11 treatment in a model of neuropathic pain. In PSNI (day
three) nerve injured rats, 100 nM galanin and Gal2-11 s.c. enhanced mechanical activity in nociceptive afferents, whereas 10 uM galanin and
Gal2-11 s.c. inhibited mechanical activity. [A] 100 nM galanin significantly reduced mechanical thresholds (one way ANOVA with post-hoc
Bonferroni multiple comparison test, *p < 0.05, n = 5), and similarly [B] 100 nM Gal2-11 significantly reduced mechanical thresholds (one way
ANOVA with post-hoc Bonferroni multiple comparison test, ** p < 0.01, n = 3). [C] 10 uM galanin significantly increased mechanical activation
thresholds (one way ANOVA with post-hoc Bonferroni multiple comparison test, **p < 0.01, n = 4), and similarly [D] 10 uM Gal2-11 significantly
increased mechanical activation thresholds (one way ANOVA with post-hoc Bonferroni multiple comparison test, * P < 0.05, n = 5).
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activation thresholds of nociceptive afferents. The mag-
nitude of these changes was very similar to that
observed in the intact rat. Previous work by Wiesenfeld-
Hallin had shown that the depressive effect of i.t. gala-
nin on the flexor reflex occurred more often and at
lower doses of galanin after sciatic nerve axotomy com-
pared to intact rats [12]. We have not tested whether
lower doses (e.g. 1 uM) of galanin or Gal2-11 would
also cause a decrease in mechanically-evoked activity of
nociceptive afferents in the PSNI model but not in the
intact state, though one would predict that a similar
finding would be observed.
The application of the PSNI model to the Gal-OE
transgenic mice, which over express galanin in the
DRG, spinal cord and brain, demonstrated a reversal in
allodynia in the Gal-OE mice. These findings are paral-
leled by an abolition in nociceptor spontaneous activity
and the calculated afferent barrage into the spinal
cord, further supporting a peripheral anti-nociceptive
role for galanin/GalR2. After nerve injury the raised
levels of endogenous galanin in the DRG and in the
nerve trunk following anterograde transport of galanin
from the cell body to the site of injury [46], could
exert a direct inhibitory effect on primary afferent
fibres via activation of GalR2, leading to a marked
reduction in spontaneous neuronal firing and C-fibre
barrage into the spinal cord and thus an attenuation in
neuropathic pain behaviour. At present we are unable
to separate the effects of the galanin overexpression in
the DRG of these transgenic mice from that in the
spinal cord and/or brain. It is only when galanin drug-
like agonists are characterized that do or do not pene-
trate the blood-brain barrier, that their specific sites of
action can be systematically tested.
In the present study we have shown that the biphasic
nociceptive responses to peripherally administered gala-
nin and the GalR2/3-specific ligand Gal2-11 (which does
not activate GalR1 [26]) in intact and nerve injured rats
are almost identical. Further, levels of GalR3 mRNA
expression in the DRG and dorsal horn are undetectable
by in-situ hybridization [25] and only barely detectable
in the DRG using RT-PCR [21], and do not appear to
change after peripheral nerve injury [21]. These findings
imply that the above effects of galanin and Gal2-11 are
most likely to be mediated by activation of GalR2. How-
ever further investigation into the relative involvement
of GalR1 and GalR2 in nociception are not possible at
present due to the current lack of drug-like pharmacolo-
gical tools that are GalR1- and GalR2-specific.
To date, the majority of published work using the
GalR2/3 specific agonist Gal2-11 has shown that central
GalR2 activation plays a predominantly stimulatory role
with regard to nociception. Intrathecal infusion of low
dose Gal2-11 in the intact rat reduces mechanosensory
thresholds [26] and peripheral administration of the
agonist in the low nanomolar range into the peripheral
receptive field facilitates inflammatory pain behaviours
[47]. Consistent with this, ~70% of dispersed adult rat
sensory neurons in culture responded to galanin and
Gal2-11, via coupling to Gq/11 which leads to an
increase in calcium influx and neuronal excitability [18].
These results have led many to hypothesise that activa-
tion of GalR1 is inhibitory and plays an anti-nociceptive
role whilst GalR2 is excitatory and pro-nociceptive [48].
More recently however, further data has shown that
GalR2 activation may also be inhibitory with regard to
nociception. Smith and colleagues have shown that acti-
vation of GalR2 in the presynaptic terminals of the dor-
sal horn of the spinal cord can lead to the inhibition of
sensory neuron excitability, compatible with an anti-
nociceptive role for the receptor [49]. Similarly, work by
Wiesenfeld-Hallin and colleagues has shown that i.t.
administration of micromolar doses of galanin robustly
inhibited windup and reflex facilitation in intact GalR1-
KO mice, confirming that GalR2 activation in the spinal
cord can also be inhibitory with respect to nociception
[50]. This conclusion is further strengthened by recent
work by the Stebbing lab demonstrating that GalR2 acti-
vation directly inhibits calcium currents in dispersed
cultured DRG neurons [51] and provides a precedented
mechanism of action by which GalR2 activation in the
DRG may reduce nociception.
Figure 6 The effects of 10uM galanin and 10uM Gal2-11 on
nociceptive C-fibres in intact and nerve injured rats. C fibre
mechanical responses from intact and nerve injured rats after
galanin treatment were normalised to baseline. [A] In intact naïve
rats galanin and Gal2-11 were equipotent in increasing mechanical
thresholds. [B] Similarly, three days after PSNI, galanin and Gal2-11
both equally increased mechanical thresholds.
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The mechanism(s) by which activation of GalR2 by
low dose galanin or Gal2-11 facilitates nociceptor and
spinal flexor reflex activity and inhibits these same
neurons at higher doses are unclear. Studies using in-
situ hybridization (there are no antisera specific for
either receptor subtype that can be used for immuno-
cytochemistry) have shown that the majority of the
neurons in the DRG express both GalR1 and GalR2
mRNAs [18] whilst in the dorsal horn GalR1 expres-
sion predominates [22]. It is possible therefore that the
observed dose-dependent responses to galanin and
Gal2-11 might be explained in part by differing
responses of subpopulations of neurons that express
varying levels of GalR1 or GalR2. However, our find-
ings that galanin and the GalR2/3 agonist Gal2-11
have very similar dose-dependent actions on mechano-
sensory thresholds in the intact animals and after
nerve injury makes this explanation less likely, and
implies the dual effects are both mediated by activation
of GalR2. It is now well established that GalR2 couples
both to Gi (inhibiting adenylyl cyclase and thus noci-
ception) and to Gq/11 (which in turn activates MAPK
and Akt, reviewed in [52], and thus may play a pro-
nociceptive role). The kinetics of these two pathways
in the DRG and the spinal cord are unknown and it is
possible that the Gq/11 pathway “saturates” and reaches
maximum before Gi. Thus as the dose of galanin or
Gal2-11 is increased the inhibitory downstream signal-
ling pathway becomes predominant explaining why
both ligands are anti-nociceptive at micromolar
Figure 7 Alterations in mechanical allodynia and primary afferent nociceptor mechanical responses in transgenic galanin over-
expressing mice. Transgenic mice that over-express galanin (Gal-OE) recover rapidly from PSNI-induced mechanical allodynia, compared to WT
mice. [A] WT and Gal-OE mice have similar baseline mechanical responses before PSNI. Following surgery at day 0 (dotted line), WT mice
develop robust mechanical allodynia when compared to baseline values (one way ANOVA with post-hoc Bonferroni multiple comparison test, #
p < 0.001, n = 10). Gal-OE mice initially developed mechanical allodynia (one way ANOVA with post-hoc Bonferroni multiple comparison test,
day 1 $ p < 0.001, day 3 & p < 0.01, n = 10) but by day 4 mechanical withdrawal thresholds had recovered to baseline values and were
significantly different to WT thresholds (two way ANOVA with post-hoc Bonferroni multiple comparison test, ** p < 0.01, *** p < 0.001, n = 10,).
[B] Mechanical activation thresholds of nociceptive afferents were significantly increased in the nerve injured (NI day 7) Gal-OE mice compared
to uninjured Gal-OE and WT mice (one way ANOVA with post-hoc Bonferroni multiple comparison test, * p < 0.05, Intact WT n = 3, NI WT n = 4,
Intact Gal-OE n = 7, NI Gal-OE n = 4). [C] The mechanical activation threshold of mechano-sensitive A fibres were unchanged in the Gal-OE
mouse compared to the WT in both intact and PSNI (intact WT n = 4, NI WT n = 3, intact Gal-OE n = 7, NI Gal-OE n = 5).
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concentrations. Evidence for opposing G-protein regu-
lated transduction pathways with differing concentra-
tions of ligands in GPCRs, comes from work by
Teschemacher who showed that low doses of angioten-
sin II inhibit exocytosis in a Gi-dependent manner in
chromaffin cells, whilst high concentrations of ligand
potentiate catecholamine release via activation of PLC
and calcium mobilisation from internal stores [53].
Similarly, low doses of agonist activate beta-2 adrener-
gic receptors through Gas whilst high concentrations
are transduced via a G-protein-independent pathway
that appears to require the Src tyrosine kinase [54].
Both of these papers are analogous to our current data
and that of Wiesenfeld-Hallin, and again support the
hypothesis that the observed dose-dependent agonist
effects on nociception are mediated by GalR2 via dif-
ferent intracellular signalling pathways.
Our current findings and those of Wiesenfeld-Hallin
raise the issue of whether the local extra-cellular levels
of galanin after nerve injury are sufficient to inhibit
nociceptive responses via activation of GalR1 and/or
GalR2. Previous work by Duggan et al using antibody
microprobes has shown an extensive basal release of
galanin in the dorsal horn of intact adult rats, with a
significant rise in release in the superficial layer of the
cord ipsilateral to peripheral nerve injury [55,56]. These
studies have not been extended to the DRG nor was
quantitation of the absolute extra-cellular levels of gala-
nin possible using the antibody microprobe technique.
In the current study and that of Wiesenfeld-Hallin,
micromolar amounts of galanin were injected s.c. into
the paw or by bolus i.t. injection into the lumbar enlar-
gement respectively, and in both cases the local concen-
tration at the receptor terminals will inevitably have
been reduced by a combination of local tissue dilution
and degradation.
In summary, we have demonstrated yet another
layer of complexity in the “galanin pain story”. Our
data supports the hypothesis that peripheral activation
of GalR2 by the raised levels of endogenous galanin in
injured primary afferents increases C-fibre thresholds
and decreases evoked and spontaneous activity. These
changes in primary afferent properties lead to a
decrease in C-fibre barrage into the spinal cord which
would be expected to reduce central sensitisation and
allodynia. These findings will need to be further sub-
stantiated in intact rodents and the neuropathic pain
models described above, once GalR2-specific drug-like
agonists are identified and characterized. Of note, the
previously described loss of a subset of small diameter
unmyelinated neurons that are likely to be nociceptors
in the DRG of Gal-KO [57] and GalR2-KO mice [21],
precludes the use of these mice to further analyse the
nociceptive role played by GalR2 in the adult animal.
Similarly, immunoneutralising antisera against galanin
that can be used in-vivo have yet to be described.
Materials and methods
Experiments were performed on 8 week old male Wistar
rats and 8 week old male Gal-OE and strain matched
wildtype (WT) CBA/Bl6 mice [17,36]. Animals were fed
standard chow and water ad libitum and all experiments
were carried out in accordance with the United King-
dom Animals (Scientific Procedures) Act 1986. In accor-
dance with UK legislation, in all experiments the
minimum numbers of animals were used to achieve sta-
tistical significance.
Partial saphenous nerve ligation injury (PSNI) was
performed as previously described [33,34,37]. Anaesthe-
sia was induced and maintained with either isoflurane
or halothane in O2 (3% induction, 2% maintenance). An
incision was made in the inguinal fossa of the right hind
leg exposing the superficial saphenous nerve. The saphe-
nous nerve was isolated proximal to any branch points
using blunt dissection with fine forceps from the sur-
rounding tissues. PSNI surgery prior to electrophysiogi-
cal experiments had to be positioned to allow sufficient
nerve proximal to the injury site to allow recordings to
be made. A size 4.0 sterile silk suture in rat (size 7.0 in
mice) was used to ligate ~50% of the total nerve, with
the lateral half of the nerve being ligated for consistency.
The skin was sutured with a 4.0 sterile silk suture. Ani-
mals were monitored and allowed to recover thereafter
for the duration of the experiments. Electrophysiological
experiments were carried out three days after PSNI in
rat and seven days in mice.
Electrophysiology
Anaesthesia was induced with sodium pentobarbital (60
mg/kg i.p. rats, 10 mg/kg i.p. mice, Sigma-Aldrich, UK)
and were then maintained deeply anaesthetised and are-
flexive using continuous infusion of sodium pentobarbi-
tal (~20 mg/kg/hr i.v. via an external jugular cannula in
rat, and ~2 mg/kg/hr i.p. mice). Body temperature was
maintained within physiological limits by means of a
feedback controlled heater and rectal thermister. At the
end of all experiments, rats and mice were killed by an
overdose of sodium pentobarbital.
An incision was made along the right inguinal fossa to
expose the saphenous nerve. Using blunt dissection,
skin was freed from surrounding tissue and this was
used to create a pool. To keep the tissue hydrated the
pool was filled with warmed mineral oil. In the mouse,
the pool was lined with Xantopren XL, which set once
mixed with Activator Universal (Heraeus Kulzer, Ger-
many). This prevented mineral oil leakage, due to the
porosity of mouse skin. The saphenous nerve was
exposed and the epineurium was removed to allow fine
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filaments to be dissected from the main trunk of the
nerve. Filaments were placed on bipolar platinum
recording electrodes for differential recordings of neuro-
nal activity to identify individual afferent fibres. After
nerve injury, recordings were made proximal to the site
of injury. This recorded activity was amplified, filtered
and captured for off-line analysis by a micro1401 (Cam-
bridge Electronic Design, U.K) and P.C interface (Vig-
len) using Spike 2 software (C.E.D. Cambridge, UK).
A search protocol was used to identify afferents that
innervated the hindpaw (no higher than the ankle) and
had identifiable receptive fields. Initial characterisation
of afferents involved mechanical search stimulus (brush/
glass rod/probe/pinch with blunt forceps) and monopo-
lar electrical search stimulation. The mechanical search
stimulus was used to apply pressure to discrete areas of
the foot to stimulate robust responses from mechani-
cally sensitive afferents. Electrical stimulation involved
the use of a monopolar (cathode) electrode. The mono-
polar electrode was used to determine conduction velo-
city (CV) for fibres in m/s. This was applied to the
receptive field on the hindpaw (0.5 ms duration, at max.
100V intensity, rate 0.3Hz). The CV for afferents were
defined as C-fibres <1 m/s, and A-fibres as >1 m/s
[58,59]. These stimuli allowed the identification and
characterisation of individual mechano-sensitive affer-
ents. To ensure that recordings acquired were from one
individual afferent, afferents were teased to ensure that
there were minimal numbers of fibres with receptive
fields in the hindpaw and that there was minimal over-
lap of these receptive fields. Offline sorting analysis of
waveforms using Spike 2 software (C.E.D.) confirmed
responses to be from an individual afferent fibre.
Once a single primary afferent receptive field had been
identified, it was further characterised. Brush, pinch with
blunt forceps and the use of direct calibrated force with
von Frey hairs (Linton instruments, UK) were all applied
to the receptive field to determine mechanical response
properties. Mechanical thresholds were identified by
applying a range of von Frey (vF) hairs, with each vF
applied no more than three times to the receptive field
for 5 seconds as previously described [58,60-62]. Using
an up down method, the lowest force that reproducibly
elicited robust firing (firing >3 action potentials) of the
identified afferent fibre was determined to be the
mechanical threshold [59,63]. Nociceptive (or high
threshold mechano-sensitive (HTM)) afferents
responded to pinch when applied to the receptive field
but not brush, typically von Frey activation thresholds
were above 1 g [33,58]. In the mouse, nociceptive affer-
ents (were not brush sensitive) were derived from
pooled C- and A-delta fibre groups. Mechanically
evoked activity was also recorded by applying a range of
von Frey hairs (rat; 0.4 g-180 g mouse; 0.16-2 g) to the
receptive field for 5 seconds, each hair being applied
three times. Following the mechanical characterisation
of the afferent, these responses were also recorded after
vehicle and drug administration. The operator was
blinded to mouse genotype throughout the experiments.
Mechano-nociceptor afferent activation threshold data
in intact naïve and PSNI groups after galanin or Gal2-
11 injections were normalised to the respective mean
baseline thresholds, allowing direct comparisons
between the groups. The total primary afferent barrage
was calculated as previously described [37], from the
numbers of unmyelinated afferents in the saphenous
nerve [64,65]. This value was multiplied by the mean
value of ongoing activity and if the nerve was injured,
the value was divided by two to represent the 50% of
the saphenous nerve left intact.
Drug administration
Vehicle and drugs were administered using an insulin
needle (BD micro fineTM). 30ul subcutaneous injections
(s.c.) were administered just outside the identified recep-
tive field. The initial s.c. injection involved injecting 30ul
of vehicle (saline) thirty minutes after characterisation of
the afferents. Five minutes later mechanical thresholds
and evoked activity were recorded. If mechanical activa-
tion thresholds and/or mechanical evoked activity were
significantly diminished by the vehicle injection (imply-
ing local tissue damage or inflammation, resulting in
changes in afferent properties), the effect of the drug
was not investigated. If afferent properties were
unchanged by vehicle then the drug was injected at the
same site thirty minutes after vehicle injection. Mechan-
ical thresholds and evoked activity were determined at
one and/or five minutes after injection. At one minute,
only the activation threshold was identified due to the
time constraints of the experiment. Different concentra-
tions of galanin (rat, Bachem UK) and the GalR2/3 ago-
nist Gal2-11 (Sigma-Aldrich, UK) were administered.
Repeated vehicle (saline) injections showed no change in
mechanical activation threshold (data not shown).
Behavioural Testing
The day prior to behavioural testing mice were placed in
transparent perspex enclosures and habituated to the
testing environment for a minimum of 15 minutes until
they settled. Habituation occurred prior to all beha-
vioural testing sessions. Mechanical withdrawal thresh-
olds were recorded from both ipsilateral and
contralateral hind paws. Mechanical withdrawal thresh-
olds were determined using a series of calibrated von
Frey filaments (Linton Instruments, UK). Each von Frey
hair ranging from 0.16 g to 2 g was applied to the med-
ial plantar surface of each hindpaw 5 times for a maxi-
mum period of 5 seconds or until a withdrawal was
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elicited. The 50% mechanical withdrawal thresholds (the
force at which the animal withdrew the paw 50% of the
time), were then calculated from stimulus/response
curves, generated as previously described [33,37,58].
Statistical Analysis
Data are shown as mean ± SEM. Mechanically evoked
activity before and after drug along with mechanical
withdrawal testing were compared using one way
ANOVA with post hoc Bonferroni tests (* p < 0.05, ** p
< 0.01, *** p < 0.001). Activation thresholds were com-
pared using either one-way ANOVAs with post hoc
Bonferroni multiple comparison test or paired T test (*
p < 0.05, ** p < 0.01, *** p < 0.001).
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